Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HUC-MSCs (Human Umbilical Cord Mesenchymal Stem Cells) is an investigational cell therapy developed by the Chinese Academy of Sciences for the treatment of primary ovarian insufficiency (POI). The therapy involves the intraovarian transplantation of mesenchymal stem cells derived from human umbilical cord tissue. These cells function primarily through paracrine mechanisms, secreting growth factors such as vascular endothelial growth factor A (VEGFA) to restore ovarian function. The treatment aims to reduce apoptosis in ovarian granulosa and theca interstitial cells, alleviate excessive autophagy, and promote tissue repair via the PI3K/AKT/mTOR and NR4A1-mediated mitochondrial pathways. Clinical evaluation has focused on safety and efficacy in women aged 20-40, often in combination with hormone replacement therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human umbilical cord mesenchymal stem cells (Chinese Academy of Sciences).